Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Syrian first lady Asma Assad diagnosed with leukemia, president's office says
Fall in love with Chinese instrument hulusi flute
Mark Wahlberg, 52, flaunts his muscles in shirtless video flexing during 4am workout
Antiwar protesters' calls for divestment at universities put spotlight on endowments
Warner holds out IPL hot shot Fraser
These are the countries where TikTok is already banned
Bevy of defensive playmakers are available in Round 2 of the NFL draft after historic offensive run
AP Week in Pictures: Europe and Africa
Seoul AI summit opens with companies including Google, Meta, OpenAI pledging to develop AI safely
More doctors can prescribe a leading addiction treatment. Why aren't more people getting help?